Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile.

Drugs R D · 2026 · PMC13076708 · PMID 41746497

Europe PMC DOI

hedged sentences

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantp < 0.01actually significant

Statistical differences between groups were considered significant at p < 0.05, highly significant at p < 0.01, and extremely significant at p < 0.001.

also in 132,142 other papers

a decreasing trendno p-value reported

During the treatment period, the body weight of mice in each group showed a decreasing trend over time (Fig. 3 d).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.